Do analysts rate LYRA or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,125.66%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend VCNX or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is VCNX or LYRA more profitable?

Vaccinex has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Vaccinex's return on equity of 0.00% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts prefer SXTC or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China SXT Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings & valuation, SXTC or LYRA?

China SXT Pharmaceuticals has higher revenue and earnings than Lyra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio China SXT Pharmaceuticals $1.14M 120.36 -$6.20M N/A N/A Lyra Therapeutics $600K 0.83 -$93.43M -$19.15 N/A

Do analysts rate LYRA or GRI?

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LYRA or GRI more profitable?

GRI Bio has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GRI Bio's return on equity of -199.52% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lyra Therapeutics -5,491.17% -1,010.91% -58.92% GRI Bio N/A -199.52% -143.23%

Do analysts rate NXTS or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Lyra Therapeutics (LYRA) Competitors

$0.28 -0.06 (-17.65%)

As of 08/10/2026 03:28 PM Eastern

Compare

LYRA vs. SXTP, VCNX, SXTC, GRI, and NXTS

Should you buy Lyra Therapeutics stock or one of its competitors? Lyra Therapeutics's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTP), Vaccinex (VCNX), China SXT Pharmaceuticals (SXTC), GRI Bio (GRI), and Nexentis Technologies (NXTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lyra Therapeutics compare to 60 Degrees Pharmaceuticals?

Lyra Therapeutics (NASDAQ:LYRA) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lyra Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than Lyra Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	0.83	-$93.43M	-$19.15	N/A
60 Degrees Pharmaceuticals	$1.41M	2.13	-$7.36M	-$8.92	N/A

60 Degrees Pharmaceuticals has a net margin of -574.91% compared to Lyra Therapeutics' net margin of -5,491.17%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
60 Degrees Pharmaceuticals	Neutral

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,125.66%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

60 Degrees Pharmaceuticals beats Lyra Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Lyra Therapeutics compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Vaccinex has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Vaccinex has higher earnings, but lower revenue than Lyra Therapeutics. Vaccinex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	6.63	-$20.25M	-$48.27	N/A
Lyra Therapeutics	$600K	0.83	-$93.43M	-$19.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Vaccinex has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Vaccinex's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, Vaccinex had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for Lyra Therapeutics. Vaccinex's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Lyra Therapeutics	Neutral

50.1% of Vaccinex shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 51.5% of Vaccinex shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Vaccinex beats Lyra Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Lyra Therapeutics compare to China SXT Pharmaceuticals?

China SXT Pharmaceuticals (NASDAQ:SXTC) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

China SXT Pharmaceuticals has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China SXT Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

China SXT Pharmaceuticals has higher revenue and earnings than Lyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China SXT Pharmaceuticals	$1.14M	120.36	-$6.20M	N/A	N/A
Lyra Therapeutics	$600K	0.83	-$93.43M	-$19.15	N/A

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

China SXT Pharmaceuticals has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. China SXT Pharmaceuticals' return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China SXT Pharmaceuticals	N/A	N/A	N/A
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, China SXT Pharmaceuticals had 3 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for China SXT Pharmaceuticals and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 beat China SXT Pharmaceuticals' score of -0.67 indicating that Lyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
China SXT Pharmaceuticals	Negative
Lyra Therapeutics	Neutral

Summary

China SXT Pharmaceuticals beats Lyra Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to GRI Bio?

Lyra Therapeutics (NASDAQ:LYRA) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Lyra Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market.

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by insiders. Comparatively, 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GRI Bio has lower revenue, but higher earnings than Lyra Therapeutics. GRI Bio is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	0.83	-$93.43M	-$19.15	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

GRI Bio has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. GRI Bio's return on equity of -199.52% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
GRI Bio	N/A	-199.52%	-143.23%

GRI Bio has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts plainly believe GRI Bio is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GRI Bio had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 equaled GRI Bio'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
GRI Bio	Neutral

Summary

GRI Bio beats Lyra Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Lyra Therapeutics compare to Nexentis Technologies?

Nexentis Technologies (NASDAQ:NXTS) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Nexentis Technologies' average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nexentis Technologies	Neutral
Lyra Therapeutics	Neutral

Nexentis Technologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nexentis Technologies has higher earnings, but lower revenue than Lyra Therapeutics. Nexentis Technologies is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexentis Technologies	N/A	N/A	-$4M	-$114.15	N/A
Lyra Therapeutics	$600K	0.83	-$93.43M	-$19.15	N/A

61.2% of Nexentis Technologies shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 6.5% of Nexentis Technologies shares are owned by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nexentis Technologies has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Nexentis Technologies' return on equity of -145.15% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nexentis Technologies	N/A	-145.15%	-111.82%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

Lyra Therapeutics beats Nexentis Technologies on 6 of the 11 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYRA vs. The Competition

Export

Metric	Lyra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$497K	$11.81B	$7.01B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.07%
P/E Ratio	-0.01	788.51	269.20	24.72
Price / Sales	0.83	744.73	592.83	98.22
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.03	10.32	11.39	6.42
Net Income	-$93.43M	$2.77B	$3.45B	$347.03M
7 Day Performance	-41.05%	0.86%	1.92%	0.69%
1 Month Performance	-48.09%	-1.59%	-0.57%	-0.90%
1 Year Performance	-95.80%	183.23%	75.49%	21.87%

Lyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYRA Lyra Therapeutics	N/A	$0.28 -17.6%	N/A	-95.8%	$497K	$600K	N/A	50	Gap Up
SXTP 60 Degrees Pharmaceuticals	2.4781 of 5 stars	$1.20 +3.7%	$13.85 +1,051.3%	-79.7%	$3.20M	$1.00M	N/A	3	Upcoming Earnings
VCNX Vaccinex	N/A	$1.12 -2.6%	N/A	+41.4%	$2.91M	$388K	N/A	40
SXTC China SXT Pharmaceuticals	0.8061 of 5 stars	$0.07 -3.1%	N/A	-100.0%	$2.90M	$1.14M	N/A	90	Gap Up High Trading Volume
GRI GRI Bio	1.8471 of 5 stars	$1.61 +11.5%	$32.00 +1,893.8%	-95.2%	$2.83M	N/A	N/A	1	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYRA) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyra Therapeutics (LYRA) Competitors

LYRA vs. SXTP, VCNX, SXTC, GRI, and NXTS

How does Lyra Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does Lyra Therapeutics compare to Vaccinex?

Summary

How does Lyra Therapeutics compare to China SXT Pharmaceuticals?

Summary

How does Lyra Therapeutics compare to GRI Bio?

Summary

How does Lyra Therapeutics compare to Nexentis Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyra Therapeutics (LYRA) Competitors

LYRA vs. SXTP, VCNX, SXTC, GRI, and NXTS

How does Lyra Therapeutics compare to 60 Degrees Pharmaceuticals?

Do insiders and institutionals have more ownership in LYRA or SXTP?

Which has more volatility & risk, LYRA or SXTP?

Which has better valuation and earnings, LYRA or SXTP?

Is LYRA or SXTP more profitable?

Does the media prefer LYRA or SXTP?

Do analysts rate LYRA or SXTP?

Summary

How does Lyra Therapeutics compare to Vaccinex?

Which has more risk & volatility, VCNX or LYRA?

Which has preferable valuation and earnings, VCNX or LYRA?

Do analysts recommend VCNX or LYRA?

Is VCNX or LYRA more profitable?

Does the media favor VCNX or LYRA?

Do institutionals & insiders hold more shares of VCNX or LYRA?

Summary

How does Lyra Therapeutics compare to China SXT Pharmaceuticals?

Which has more risk and volatility, SXTC or LYRA?

Do analysts prefer SXTC or LYRA?

Which has stronger earnings & valuation, SXTC or LYRA?

Do institutionals and insiders hold more shares of SXTC or LYRA?

Is SXTC or LYRA more profitable?

Does the media favor SXTC or LYRA?

Summary

How does Lyra Therapeutics compare to GRI Bio?

Which has more volatility & risk, LYRA or GRI?

Do insiders and institutionals hold more shares of LYRA or GRI?

Which has higher earnings & valuation, LYRA or GRI?

Is LYRA or GRI more profitable?

Do analysts rate LYRA or GRI?

Does the media refer more to LYRA or GRI?

Summary

How does Lyra Therapeutics compare to Nexentis Technologies?

Does the media favor NXTS or LYRA?

Which has more volatility and risk, NXTS or LYRA?

Do analysts rate NXTS or LYRA?

Which has better earnings & valuation, NXTS or LYRA?

Do insiders & institutionals have more ownership in NXTS or LYRA?

Is NXTS or LYRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools